L1210/DTIC antigenic subline: studies at the clone level.
Treatment of murine tumors with the anti-tumor agent 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) has resulted in the induction of antigenic specificities not found in parental cells. After the withdrawal of DTIC treatment, the antigenic sublines maintained the new properties indefinitely, as a heritable character although the mechanism of induction and the molecular nature of the new antigens are essentially unknown. Seven clones from the murine immunogenic leukemia L1210/DTIC were selected and studied in some detail. Three of the seven clones showed an increased immunogenicity in vivo since two clones (D5 and D7) were rejected by syngenic mice and one (D6) prolonged the life span for 3 weeks (untreated tumours killed the mice in 7 days). The seven clones and the L1210/DTIC were recognized and lysed by in vivo primed, in vitro stimulated (with L1210/DTIC) lymphocytes. Therefore, the seven clones shared antigens with the L1210-DTIC immunogenic subline. Secondary stimulated lymphocytes to clone D5, and clone D7 were able to lyse D5, D6 and D7 cells, respectively, but were unable to recognize the remaining clones. From in vivo and in vitro studies, all the L1210/DTIC sublines are composed of cells carrying two or more distinct antigens. Each cell clone expressed one set of antigens. It was concluded that only a few antigens expressed in different cells were induced by a DTIC treatment of L1210 leukemia.
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis*; D002460:Cell Line; D002999:Clone Cells / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D003606:Dacarbazine / Q000494:pharmacology*; D000939:Epitopes / Q000032:analysis*; D005260:Female; D007939:Leukemia L1210 / Q000276:immunology* / Q000473:pathology; D008297:Male; D051379:Mice
D000951:Antigens, Neoplasm; D000939:Epitopes; D003606:Dacarbazine